Preparation And Storage
Recommended Assay Procedures
BD® CompBeads can be used as surrogates to assess fluorescence spillover (compensation). When fluorochrome conjugated antibodies are bound to BD® CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD® CompBeads to ensure that BD® CompBeads are appropriate for your specific cellular application.
Product Notices
- Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
- Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
- For U.S. patents that may apply, see bd.com/patents.
- Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
- Since applications vary, each investigator should titrate the reagent to obtain optimal results.
- The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
- Human donor specific background has been observed in relation to the presence of anti-polyethylene glycol (PEG) antibodies, developed as a result of certain vaccines containing PEG, including some COVID-19 vaccines. We recommend use of BD Horizon Brilliant™ Stain Buffer in your experiments to help mitigate potential background. For more information visit https://www.bdbiosciences.com/en-us/support/product-notices.
- When using high concentrations of antibody, background binding of this dye to erythroid fragments produced by ammonium chloride-based lysis, such as with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899), has been observed when the antibody conjugate was present during the lysis procedure. This may cause nonspecific staining of target cells, such as leukocytes, which have bound the resulting erythroid fragments. This background can be mitigated by any of the following: titrating the antibody conjugate to a lower concentration, fixing samples with formaldehyde, or removing erythrocytes before staining (eg, gradient centrifugation or pre-lysis with wash). This background has not been observed when cells were lysed with BD FACS™ Lysing Solution (Cat. No. 349202) after staining.
- For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
- An isotype control should be used at the same concentration as the antibody of interest.
- Please observe the following precautions: We recommend that special precautions be taken (such as wrapping vials, tubes, or racks in aluminum foil) to protect exposure of conjugated reagents, including cells stained with those reagents, to any room illumination. Absorption of visible light can significantly affect the emission spectra and quantum yield of tandem fluorochrome conjugates.
Companion Products
The BC4 antibody reacts with the high-affinity IgE Fc receptor (FcεRI) expressed in rat mast cells, basophils, and non-B non-T cells. The rat FcεRI is expressed as a tetrameric molecule consisting of one α chain, one β chain, and two identical γ chains. The BC4 antibody has been reported to detect all three chains of the FcεRI by immunoprecipitation. In the rat model, the β chain (FcRβ) is required for cell-surface expression of the complete FcεRI. This differs from the human FcεRI, which can be expressed in trimer (αγ2) or tetramer forms (βγ2). Furthermore, the FcRβ has been characterized as a potent signaling molecule capable of substantially amplifying Fc-mediated cellular responses. The FcεRI functions to mediate cellular degranulation and the release of histamine, leukotrienes, and various cytokines and chemokines. The structure, expression, function, and signaling mechanisms of the FcεRI have been reviewed.
Development References (3)
-
Basciano LK, Berenstein EH, Kmak L, Siraganian RP. Monoclonal antibodies that inhibit IgE binding. J Biol Chem. 1986; 261(25):11823-11831. (Immunogen: Immunoprecipitation, Inhibition). View Reference
-
Dombrowicz D, Nutten S, Desreumaux P. Role of the high affinity immunoglobulin E receptor in bacterial translocation and intestinal inflammation. J Exp Med. 2001; 193(1):25-34. (Biology). View Reference
-
Kinet JP. The high-affinity IgE receptor (Fc epsilon RI): from physiology to pathology. Annu Rev Immunol. 1999; 931-972. (Clone-specific: Immunofluorescence). View Reference
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.